FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Giovanni Melillo

Research Profile

Chemicals & Drugs

Physiology

Disorders

Living Beings

Mouse

Anatomy

Concepts & Ideas

Maximum Tolerated Dose

Co-author Network

Publications

TOP 3
Annamaria Rapisarda; Giovanni Melillo
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.
Annamaria Rapisarda; Giovanni Melillo
Role of the VEGF/VEGFR axis in cancer biology and therapy.
Nicole Fer; Giovanni Melillo
The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Giovanni Melillo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Annamaria Rapisarda; Giovanni Melillo
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.
Nature reviews. Clinical oncology 2012;9(7):378-90.
2012: Annamaria Rapisarda; Giovanni Melillo
Role of the VEGF/VEGFR axis in cancer biology and therapy.
Advances in cancer research 2012;114():237-67.
2011: Nicole Fer; Giovanni Melillo
The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper.
Cell cycle (Georgetown, Tex.) 2011;10(19):3228.
2011: Shivaani Kummar; Giovanni Melillo; Anthony J Murgo; Ralph E Parchment; Yves Pommier; Joel M Reid; Larry Rubinstein; Giovanna Speranza; Howard Stotler; Joseph E Tomaszewski; Lihua Wang; Marcie Weil; Yiping Zhang; Matthew Ames; William Bonner; John Carter; Alice Chen; Melinda G Hollingshead; Jiuping Ji; Lee Jia; Robert Kinders; James H Doroshow
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Cancer research 2011;71(17):5626-34.
2011: Shivaani Kummar; Martin E Gutierrez; Alice Chen; Ismail B Turkbey; Deborah Allen; Yvonne R Horneffer; Lamin Juwara; Liang Cao; Yunkai Yu; Yeong Sang Kim; Jane Trepel; Helen Chen; Peter Choyke; Giovanni Melillo; Anthony J Murgo; Jerry Collins; James H Doroshow
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
European journal of cancer (Oxford, England : 1990) 2011;47(7):997-1005.
2010: Erika Terzuoli; Maura Puppo; Annamaria Rapisarda; Badarch Uranchimeg; Liang Cao; Angelika Burger; Marina Ziche; Giovanni Melillo
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.
Cancer research 2010;70(17):6837-48.
2010: Giovanni Melillo
Editorial: T cells, not "immune" from HIF.
Journal of leukocyte biology 2010;87(3):359-61.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; Xiaohong Chen; William D Figg; Maria Zajac-Kaye; Min Chen; Seth M Steinberg; Christine A Muir; Mary Ann Yancey; Yvonne R Horneffer; Lamin Juwara; Giovanni Melillo; S Percy Ivy; Maria Merino; Len Neckers; Patricia S Steeg; BA Conley; Giuseppe Giaccone; James Doroshow; Anthony J Murgo
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2010;46(2):340-7.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; William D Figg; Giovanni Melillo; Janet Dancey; Edward A Sausville; BA Conley; Anthony J Murgo; James Doroshow
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer chemotherapy and pharmacology 2010;65(2):383-9.
2009: Annamaria Rapisarda; Robert H Shoemaker; Giovanni Melillo
Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads.
Cell cycle (Georgetown, Tex.) 2009;8(24):4040-3.
2009: Barbara Onnis; Annamaria Rapisarda; Giovanni Melillo
Development of HIF-1 inhibitors for cancer therapy.
Journal of cellular and molecular medicine 2009;13(9A):2780-6.
2009: Annamaria Rapisarda; Melinda G Hollingshead; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Bradley Gehrs; Mark Raffeld; Robert Kinders; Ralph Parchment; Miriam R Anver; Robert H Shoemaker; Giovanni Melillo
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Molecular cancer therapeutics 2009;8(7):1867-77.
2009: Anita T Tandle; Maura Calvani; Badarch Uranchimeg; David Zahavi; Giovanni Melillo; Steven Libutti
Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome.
Experimental cell research 2009;315(11):1850-9.
2009: Annamaria Rapisarda; Giovanni Melillo
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2009;12(3):74-80.
2009: Paul Klausmeyer; Qin Zhou; Dominic A Scudiero; Badarch Uranchimeg; Giovanni Melillo; John H Cardellina; Robert H Shoemaker; Ching-Jer Chang; Thomas G McCloud
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
Journal of natural products 2009;72(5):805-12.
2008: Daniela Trisciuoglio; Badarch Uranchimeg; John H Cardellina; Tamara L Meragelman; Shigeki Matsunaga; Nobuhiru Fusetani; Donatella Del Bufalo; Robert H Shoemaker; Giovanni Melillo
Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide.
Journal of the National Cancer Institute 2008;100(17):1233-46.
2008: Paul Klausmeyer; Thomas G McCloud; Badarch Uranchimeg; Giovanni Melillo; Dominic A Scudiero; John H Cardellina; Robert H Shoemaker
Separation and SAR study of HIF-1alpha inhibitory tubulosines from Alangium cf. longiflorum.
Planta medica 2008;74(3):258-63.
2007: Annamaria Rapisarda; Giovanni Melillo
UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
Oncogene 2007;26(48):6875-84.
2007: Shivaani Kummar; Martin Gutierrez; Erin R Gardner; Erin Donovan; Kyunghwa Hwang; Eun Joo Chung; Min-Jung Lee; Kim Maynard; Mikhail Kalnitskiy; Alice Chen; Giovanni Melillo; Qin C Ryan; BA Conley; William D Figg; Jane Trepel; James Zwiebel; James Doroshow; Anthony J Murgo
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5411-7.
2007: Giovanni Melillo
Targeting hypoxia cell signaling for cancer therapy.
Cancer metastasis reviews 2007;26(2):341-52.
2007: Mark Creighton-Gutteridge; John H Cardellina; Andrew G Stephen; Annamaria Rapisarda; Badarch Uranchimeg; Karen Hite; William A Denny; Robert H Shoemaker; Giovanni Melillo
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):1010-8.
2007: Giovanni Melillo
Hypoxia-inducible factor 1 inhibitors.
Methods in enzymology 2007;435():385-402.
2007: Paul Klausmeyer; Thomas G McCloud; Giovanni Melillo; Dominic A Scudiero; John H Cardellina; Robert H Shoemaker
Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors.
Planta medica 2007;73(1):49-52.
2006: Giovanni Melillo
Inhibiting hypoxia-inducible factor 1 for cancer therapy.
Molecular cancer research : MCR 2006;4(9):601-5.
2006: Eun Jung Park; Dehe Kong; Robert Fisher; John H Cardellina; Robert H Shoemaker; Giovanni Melillo
Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1.
Cell cycle (Georgetown, Tex.) 2006;5(16):1847-53.
2006: Maura Calvani; Annamaria Rapisarda; Badarch Uranchimeg; Robert H Shoemaker; Giovanni Melillo
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells.
Blood 2006;107(7):2705-12.
2006: Raffaella Melani; Fabio Sallustio; Paolo Fardin; Cristina Vanni; Marzia Ognibene; Catherine Ottaviano; Giovanni Melillo; Luigi Varesio; Alessandra Eva
Growth arrest-inducing genes are activated in Dbl-transformed mouse fibroblasts.
Gene expression 2006;13(3):155-65.
2005: Dehe Kong; Eun Jung Park; Andrew G Stephen; Maura Calvani; John H Cardellina; Anne Monks; Robert J Fisher; Robert H Shoemaker; Giovanni Melillo
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Cancer research 2005;65(19):9047-55.
2005: Zoya N Demidenko; Annamaria Rapisarda; Mercedes Garayoa; Paraskevi Giannakakou; Giovanni Melillo; Mikhail V Blagosklonny
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.
Oncogene 2005;24(30):4829-38.
2005: Qin C Ryan; Donna Headlee; Milin R Acharya; Alex Sparreboom; Jane Trepel; Joseph Ye; William D Figg; Kyunghwa Hwang; Eun Joo Chung; Anthony J Murgo; Giovanni Melillo; Yusri Elsayed; Manish Monga; Mikhail Kalnitskiy; James Zwiebel; Edward A Sausville
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
2004: Maura Puppo; sandra Pastorino; Giovanni Melillo; Annalisa Pezzolo; Luigi Varesio; Maria Carla Bosco
Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8704-19.
2004: Annamaria Rapisarda; Jessica Zalek; Melinda G Hollingshead; Till Braunschweig; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Stephen M Hewitt; Robert H Shoemaker; Giovanni Melillo
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
Cancer research 2004;64(19):6845-8.
2004: Melinda G Hollingshead; Carrie A Bonomi; Suzanne D Borgel; John P Carter; R Shoemaker; Giovanni Melillo; Edward A Sausville
A potential role for imaging technology in anticancer efficacy evaluations.
European journal of cancer (Oxford, England : 1990) 2004;40(6):890-8.
2004: sandra Pastorino; L Carta; Maura Puppo; Giovanni Melillo; Maria Carla Bosco; Luigi Varesio
Picolinic acid- or desferrioxamine-inducible autocrine activation of macrophages engineered to produce IFNgamma: an approach for gene therapy.
Gene therapy 2004;11(6):560-8.
2004: Annamaria Rapisarda; Badarch Uranchimeg; Olivier Sordet; Yves Pommier; Robert H Shoemaker; Giovanni Melillo
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications.
Cancer research 2004;64(4):1475-82.
2004: Maria Carla Bosco; Maura Puppo; sandra Pastorino; Zenghui Mi; Giovanni Melillo; Stefano Massazza; Annamaria Rapisarda; Luigi Varesio
Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(3):1681-90.
2004: Annamaria Rapisarda; Robert H Shoemaker; Giovanni Melillo
Targeting topoisomerase I to inhibit hypoxia inducible factor 1.
Cell cycle (Georgetown, Tex.) 2004;3(2):172-5.
2004: Giovanni Melillo
HIF-1: a target for cancer, ischemia and inflammation--too good to be true?
Cell cycle (Georgetown, Tex.) 2004;3(2):154-5.
2003: Tiziana Schioppa; Badarch Uranchimeg; Alessandra Saccani; Subhra K Biswas; Andrea Doni; Annamaria Rapisarda; Sergio Bernasconi; Simona Saccani; Manuela Nebuloni; Luca Vago; Alberto Mantovani; Giovanni Melillo; Antonio Sica
Regulation of the chemokine receptor CXCR4 by hypoxia.
The Journal of experimental medicine 2003;198(9):1391-402.
2003: Gordon R Macpherson; Sylvia S W Ng; Siiri L Forbes; Giovanni Melillo; Tatiana S Karpova; James McNally; Thomas P Conrads; Timothy D Veenstra; Alfredo Martinez; Frank Cuttitta; Douglas K Price; William D Figg
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Molecular cancer therapeutics 2003;2(9):845-54.
2003: Susanna M Rybak; Elena Sanovich; Melinda G Hollingshead; Suzanne D Borgel; Dianne L Newton; Giovanni Melillo; Dehe Kong; Gurmeet Kaur; Edward A Sausville
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
Cancer research 2003;63(11):2812-9.
2003: Richard A Messmann; Claudio Dansky Ullmann; Tyler Lahusen; Audrey Kalehua; Jason Wasfy; Giovanni Melillo; Ivan Ding; Donna Headlee; William D Figg; Edward A Sausville; Adrian M Senderowicz
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):562-70.
2003: Suoping Zhai; Edward A Sausville; Adrian M Senderowicz; Yuichi Ando; Donna Headlee; Richard A Messmann; Arbuck Susan; Anthony J Murgo; Giovanni Melillo; Eiichi Fuse; William D Figg
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anti-cancer drugs 2003;14(2):125-35.
2002: Antoinette R Tan; Donna Headlee; Richard A Messmann; Edward A Sausville; Arbuck Susan; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4074-82.
2002: Annamaria Rapisarda; Badarch Uranchimeg; Dominic A Scudiero; Mike Selby; Edward A Sausville; Robert H Shoemaker; Giovanni Melillo
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Cancer research 2002;62(15):4316-24.
2002: Annamaria Rapella; Anna Negrioli; Giovanni Melillo; sandra Pastorino; Luigi Varesio; Maria Carla Bosco
Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma.
International journal of cancer. Journal international du cancer 2002;99(5):658-64.
2002: Robert H Shoemaker; Dominic A Scudiero; Giovanni Melillo; Michael J Currens; Anne P Monks; Alfred A Rabow; David G Covell; Edward A Sausville
Application of high-throughput, molecular-targeted screening to anticancer drug discovery.
Current topics in medicinal chemistry 2002;2(3):229-46.
2001: L Carta; sandra Pastorino; Giovanni Melillo; Maria Carla Bosco; Stefano Massazza; Luigi Varesio
Engineering of macrophages to produce IFN-gamma in response to hypoxia.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(9):5374-80.
2000: Maria Carla Bosco; Annamaria Rapisarda; Stefano Massazza; Giovanni Melillo; H Young; Luigi Varesio
The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(6):3283-91.
1999: Mikhail V Blagosklonny; Won G An; Giovanni Melillo; Phuongmai Nguyen; Jane Trepel; Leonard M Neckers
Regulation of BRCA1 by protein degradation.
Oncogene 1999;18(47):6460-8.
1999: Giovanni Melillo; Edward A Sausville; K Cloud; Tyler Lahusen; Luigi Varesio; Adrian M Senderowicz
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
Cancer research 1999;59(21):5433-7.
1999: Konstantin Salnikow; Won G An; Giovanni Melillo; Mikhail V Blagosklonny; Max Costa
Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors.
Carcinogenesis 1999;20(9):1819-23.
1997: Lynn S Taylor; G W Cox; Giovanni Melillo; Maria Carla Bosco; Igor Espinoza-Delgado
Bryostatin-1 and IFN-gamma synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages.
Cancer research 1997;57(12):2468-73.
1997: Giovanni Melillo; Lynn S Taylor; A Brooks; Tiziana Musso; G W Cox; Luigi Varesio
Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine.
The Journal of biological chemistry 1997;272(18):12236-43.